Case Report: Rare adverse events following CAR-T therapy in patients with relapsed/refractory diffuse large B-cell lymphoma
{{output}}
Chimeric antigen receptor T-cell (CAR-T) therapy is a significant development in cancer therapy that is used to treat B-cell malignancies including B cell lymphoblastic leukemias, relapsed and refractory lymphomas, and multiple myeloma. CAR-T requires T-cell c... ...
